Qiagen NV
$ 41.04
-0.48%
20 Apr - close price
- Market Cap 8,457,308,000 USD
- Current Price $ 41.04
- High / Low $ 41.23 / 40.83
- Stock P/E 20.12
- Book Value 18.33
- EPS 2.04
- Next Earning Report 2026-05-06
- Dividend Per Share $0.26
- Dividend Yield 0.64 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 57.82
- 52 Week Low 38.80
About
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Analyst Target Price
$53.96
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-30 | 2024-04-28 | 2024-02-05 | 2023-10-30 | 2023-08-08 | 2023-05-02 |
| Reported EPS | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | -0.9 | 0.5 | 0.6 | 0.56 | 0.57 | 0.57 |
| Estimated EPS | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.48 | 0.47 | 0.6 | 0.54 | 0.56 | 0.51 |
| Surprise | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | -1.38 | 0.03 | 0 | 0.02 | 0.01 | 0.06 |
| Surprise Percentage | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | -287.5% | 6.383% | 0% | 3.7037% | 1.7857% | 11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.55 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|
| Payment Date | None | 2025-07-10 | None | None |
| Amount | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QGEN
2026-04-21 07:40:04
Qiagen N.V. is a leader in molecular diagnostics, offering tools for genetic material detection and analysis, vital for genomic research and personalized medicine. The company's "sample to insight" model, relying on high-margin consumables and automation, provides a stable revenue stream and positions it for growth in areas like liquid biopsies and companion diagnostics. While facing competition from giants like Thermo Fisher and Roche, Qiagen's strong IP, strategic acquisitions, and global distribution network give it a defensible niche, making it an attractive investment for those seeking exposure to the growing genomics market.
2026-04-20 20:38:50
The article highlights Qiagen N.V.'s strategic position in the molecular diagnostics market, emphasizing its "sample-to-insight" technology as a stable investment opportunity for U.S. and English-speaking investors. It details how Qiagen's focus on enabling technologies, rather than direct drug development, provides exposure to booming biotech demand with lower volatility and reduced R&D risks. The company's core business model, key growth drivers, competitive advantage, and relevance for international investors are discussed, alongside potential risks and analyst views.
2026-04-20 02:10:23
Qiagen N.V. (NL0012169213) is highlighted as a compelling investment opportunity for U.S. and English-speaking investors due to its leadership in genomics, particularly in sample preparation and molecular analytics. The company's consumables-driven "sample-to-insight" business model generates recurring revenue and high margins, positioning it strongly within high-growth sectors like oncology and infectious disease testing. Analysts maintain favorable views on the stock, emphasizing its resilience, growth potential from precision medicine, and strong cash flow generation despite competitive risks.
2026-04-19 22:38:50
This article provides the Q3 2025 earnings call transcript for Qiagen NV (NYSE: QGEN). It highlights key positive points such as exceeding targets with 6% net sales growth, expanding into the AI-driven single-cell market via acquisition, and announcing a $500 million share repurchase. Negative points include a decline in the Asia-Pacific region, currency headwinds, and cautious capital spending impacting instrument sales.
2026-04-19 21:10:23
Barclays has maintained its "Hold" rating on Qiagen NV (QGEN.US) stock, keeping the target price at $44. This indicates the analyst believes the stock will perform in line with the market and its current valuation is fair.
2026-04-19 14:09:49
QIAGEN N.V. is positioned as a leader in molecular diagnostics and sample technologies, offering essential tools for life sciences and healthcare breakthroughs. The company's business model, heavily reliant on high-margin consumables and recurring revenue, provides stability and exposure to the expanding genomics sector and precision medicine. While supported by strong analyst views and market tailwinds, investors should consider risks like reimbursement pressures, competition, and forex volatility.
